^
Association details:
| Biomarker: | Chr amplification(15)(q22.31) |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | cisplatin (DNA synthesis inhibitor) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
692P - Copy number alterations and response to radiotherapy + cisplatin vs radiotherapy + cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
Published date:
09/05/2022
Excerpt:
LA-SCCHN who received 3 cycles of ICT (concomitant docetaxel, cisplatin, and 5-fluorouracil; TPF) followed by cisplatin plus radiotherapy (cis+RT) or cetuximab plus radiotherapy (cet+RT)...Regards to response Cis +RT, gains on 15q22.31 was associated with CR/PR cases.